IRF4 and myelodysplastic syndrome: This cross-disease consensus underscores the central importance of IRF4 in hematological malignancies, suggesting that the downregulation of IRF4 in MDS, as a subset of myeloid disorders, may represent a shared critical biological feature among these diseases.